[go: up one dir, main page]

BR9804504A - Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas - Google Patents

Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas

Info

Publication number
BR9804504A
BR9804504A BR9804504-0A BR9804504A BR9804504A BR 9804504 A BR9804504 A BR 9804504A BR 9804504 A BR9804504 A BR 9804504A BR 9804504 A BR9804504 A BR 9804504A
Authority
BR
Brazil
Prior art keywords
isoquinoline
chlorine
hydrogen
preparation
pharmaceutical substances
Prior art date
Application number
BR9804504-0A
Other languages
English (en)
Other versions
BR9804504B1 (pt
Inventor
Klaus Dr Weidmann
Karl Heinz Dr Baringhaus
Georg Dr Tschank
Ulrich Dr Werner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9804504A publication Critical patent/BR9804504A/pt
Publication of BR9804504B1 publication Critical patent/BR9804504B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"ISOQUINOLINA-3-CARBOXAMIDAS SUBSTITUìDAS, SUA PREPARAçãO E SEU USO COMO SUBSTâNCIAS FARMACêUTICAS"<D>. As isoquinolina-3-carboxamidas da fórmula I em que R~ 1~ é hidrogênio ou cloro, R² é hidrogênio, alquila, alcóxi, cloro, trifluormetila, hidroxila, ou benzilóxi, o qual é opcionalmente substituído, ou fluoralcóxicóxi da fórmula O-[CH~ 2~]~ x~-C~ f~H~ (2f+1-g)~F~ g~, onde x = 0 ou 1, f = 1 - 5 e g = 1 a (2f+1), R³ é hidrogênio, alquila, alcóxi, flúor, cloro, ciano, trifluormetila, hidroxila, ou benzilóxi, o qual é opcionalmente substituído, ou fluoralcóxicóxi da fórmula acima descrita, R^ 4^ e R^ 5^ são hidrogênio, alquila, flúor, cloro, bromo, trifluormetila, ciano, alcóxi, ou fluoralcóxicóxi da fórmula acima descrita, incluindo os sais fisiologicamente ativos, são inibidoras fortes de prolil-4-hidroxilase, os quais não causam a esteatose.
BRPI9804504-0A 1997-10-20 1998-10-19 isoquinolina-3-carboxamidas substituÍdas, processo para a preparaÇço das mesmas e medicamento. BR9804504B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
BR9804504A true BR9804504A (pt) 2001-05-22
BR9804504B1 BR9804504B1 (pt) 2009-01-13

Family

ID=7846053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9804504-0A BR9804504B1 (pt) 1997-10-20 1998-10-19 isoquinolina-3-carboxamidas substituÍdas, processo para a preparaÇço das mesmas e medicamento.

Country Status (24)

Country Link
US (1) US6093730A (pt)
EP (2) EP0911340B1 (pt)
JP (2) JP3782591B2 (pt)
KR (1) KR100618922B1 (pt)
CN (1) CN1117079C (pt)
AR (1) AR013696A1 (pt)
AT (2) ATE299148T1 (pt)
AU (1) AU755714B2 (pt)
BR (1) BR9804504B1 (pt)
CA (2) CA2250664A1 (pt)
CZ (1) CZ337298A3 (pt)
DE (3) DE19746287A1 (pt)
DK (2) DK1538160T3 (pt)
ES (2) ES2245471T3 (pt)
HU (1) HUP9802422A3 (pt)
ID (1) ID21115A (pt)
IL (1) IL126638A0 (pt)
NO (1) NO312365B1 (pt)
NZ (1) NZ332363A (pt)
PL (1) PL192354B1 (pt)
PT (1) PT911340E (pt)
SG (1) SG87776A1 (pt)
TR (1) TR199802106A3 (pt)
ZA (1) ZA989505B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528649B2 (en) 2000-05-30 2003-03-04 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
CN102552261A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
US8530404B2 (en) 2005-06-15 2013-09-10 Fibrogen, Inc. Compounds and methods for treatment of cancer
JP5202327B2 (ja) * 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
EP2044028B1 (en) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
KR100966568B1 (ko) * 2006-03-30 2010-06-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
KR101084635B1 (ko) 2006-04-04 2011-11-18 피브로겐, 인크. Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用
SI2294066T1 (sl) 2008-04-28 2014-12-31 Janssen Pharmaceutica N.V. Benzoimidazoli kot inhibitorji prolil-hidroksilaze
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
KR101850661B1 (ko) * 2009-07-17 2018-04-19 니뽄 다바코 산교 가부시키가이샤 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용
NO2686520T3 (pt) 2011-06-06 2018-03-17
ES2606631T3 (es) * 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
AU2012328763A1 (en) 2011-10-25 2014-05-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo(d)imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
JP6129217B2 (ja) 2012-03-09 2017-05-17 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物
ES2905898T3 (es) 2012-07-16 2022-04-12 Fibrogen Inc Formas cristalinas de un inhibidor de prolil hidroxilasa
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
ES2786924T3 (es) 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
US20180243271A1 (en) * 2015-05-28 2018-08-30 Japan Tobacco Inc. Method for Treating or Preventing Diabetic Nephropathy
EP3319976B1 (en) * 2015-07-09 2021-09-01 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
KR20200112872A (ko) * 2018-01-09 2020-10-05 코넬 유니버시티 장기 섬유증의 예방 및 치료
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CA3098573A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法
EP3829623A4 (en) * 2018-08-03 2022-10-19 Cornell University METHODS OF REDUCING ABNORMAL SCAR FORMATION
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DK0650960T3 (da) * 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
TW406076B (en) * 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Also Published As

Publication number Publication date
ES2245471T3 (es) 2006-01-01
DE59814365D1 (de) 2009-07-16
BR9804504B1 (pt) 2009-01-13
EP0911340A3 (de) 1999-07-07
CN1117079C (zh) 2003-08-06
HU9802422D0 (en) 1998-12-28
HK1019605A1 (en) 2000-02-18
CA2250664A1 (en) 1999-04-20
EP0911340A2 (de) 1999-04-28
TR199802106A2 (xx) 1999-05-21
JP3782591B2 (ja) 2006-06-07
DK0911340T3 (da) 2005-11-07
EP1538160B1 (de) 2009-06-03
HUP9802422A3 (en) 2002-02-28
PL192354B1 (pl) 2006-10-31
DE59812907D1 (de) 2005-08-11
KR100618922B1 (ko) 2007-04-25
DE19746287A1 (de) 1999-04-22
TR199802106A3 (tr) 1999-05-21
JP2006056894A (ja) 2006-03-02
CZ337298A3 (cs) 1999-05-12
PT911340E (pt) 2005-09-30
AR013696A1 (es) 2001-01-10
DK1538160T3 (da) 2009-10-05
IL126638A0 (en) 1999-08-17
JPH11302257A (ja) 1999-11-02
ATE432940T1 (de) 2009-06-15
EP1538160A1 (de) 2005-06-08
ES2328156T3 (es) 2009-11-10
PL329274A1 (en) 1999-04-26
AU8941398A (en) 1999-05-06
SG87776A1 (en) 2002-04-16
CN1218802A (zh) 1999-06-09
KR19990037182A (ko) 1999-05-25
EP0911340B1 (de) 2005-07-06
NZ332363A (en) 2000-04-28
CA2251647C (en) 2011-08-30
NO984877L (no) 1999-04-21
ID21115A (id) 1999-04-22
HUP9802422A2 (hu) 1999-08-30
US6093730A (en) 2000-07-25
JP4691419B2 (ja) 2011-06-01
ZA989505B (en) 1999-04-20
NO312365B1 (no) 2002-04-29
NO984877D0 (no) 1998-10-19
CA2251647A1 (en) 1999-04-20
AU755714B2 (en) 2002-12-19
ATE299148T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
BR9804504A (pt) Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas
BR9915403A (pt) Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
BR9713027A (pt) Derivados de pirazol úteis como herbicidas
DK1077928T3 (da) Nye substituerede cykliske forbindelser, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
BR9806752A (pt) Ftalazinonas.
BR9803179A (pt) Antagonistas receptores de ccr-3.
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
IS6257A (is) Frumuviðloðunartálmar
DK188288D0 (da) 1-phenyl-3-naphthalenyloxypropanaminer, fremgangsmaade til fremstilling af saadanne forbindelser og farmaceutiske midler indeholdende disse
BR9814832A (pt) Composto, e, herbicida
ES2150544T3 (es) Dihidropiridinas de accion breve.
DE60101372D1 (de) Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
ATE318810T1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
FI925848A0 (fi) Tizolidinfoereningar, som innehaoller en kinogrupp, deras framstaellning och terapeutiska anvaendningar
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
FI844333A0 (fi) 11-substituerade 5h,11h-pyrrolo/2,1-c/ /1,4/benzoxazepiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
BR0213990A (pt) Derivados de piperazina tendo atividade antagonìstica de sst1
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
SE8500107D0 (sv) Neue 8alfa-acylaminoergoline
BR0002505A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
EA200100618A1 (ru) Антагонист витронектинового рецептора

Legal Events

Date Code Title Description
TC Change of name
B25A Requested transfer of rights approved

Free format text: AWEGA PATENTMANAGEMENT GMBH (DE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: FIBROGEN, INC. (US)

Free format text: TRANSFERIDO DE: AWEGA PATENTMANAGEMENT GMBH

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/01/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.01.2019